SEC Filing Shows Inquiry on EpiPen Rebates Launched in 2014

November 11, 2016 – Media Mention
Pittsburgh Post-Gazette

Irwin Kishner was quoted in the Pittsburgh Post-Gazette regarding whether pharmaceutical company Mylan should have disclosed a two-year long federal investigation of its EpiPen drug. The question followed the announcement that Mylan had reached a preliminary $465 million settlement with the U.S. Justice Department, which was revealed during its quarterly SEC filing. "Public companies must report things that are material” in the context of their business, Kishner said. [But] not every subpoena rises to the level of materiality. The question is, at what point did they realize it was going to be a material item?”